Berlin, Germany, November 4, 2015 - Epigenomics AG, Berlin, Germany, (Frankfurt Prime Standard: ECX; ISIN: DE000A11QW50) adjusts its financial outlook for fiscal year 2015 following the FDA response letter on the Company’s lead product Epi proColon®. As communicated in the past, such a decision has a significant impact on the achievement of certain projected financial parameters for 2015.
The Company’s financial outlook for 2015 changes as follows:
Revenue is projected to exceed last year’s figure of EUR 1.5 million, which is significantly less than the projected EUR 3-4 million. In the first nine months 2015, Epigenomics recorded revenue of EUR 1.3 million* (9M 2014: EUR 1.1 million).
EBIT is now projected at the lower end, or may slightly fall short, of the previous outlook range of EUR -10.0 to -11.0 million. Cash consumption is projected at the upper end of, or may slightly exceed, the previous outlook range of EUR 9.5 to 10.5 million. *preliminary; final report on first nine months of 2015 will be published on November 18, 2015
Help employers find you! Check out all the jobs and post your resume.
The Company’s financial outlook for 2015 changes as follows:
Revenue is projected to exceed last year’s figure of EUR 1.5 million, which is significantly less than the projected EUR 3-4 million. In the first nine months 2015, Epigenomics recorded revenue of EUR 1.3 million* (9M 2014: EUR 1.1 million).
EBIT is now projected at the lower end, or may slightly fall short, of the previous outlook range of EUR -10.0 to -11.0 million. Cash consumption is projected at the upper end of, or may slightly exceed, the previous outlook range of EUR 9.5 to 10.5 million. *preliminary; final report on first nine months of 2015 will be published on November 18, 2015
Help employers find you! Check out all the jobs and post your resume.
